Atherosclerosis-targeted liposome nanocarrier delivery system and preparation method therefor
US-2024424132-A1 · Dec 26, 2024 · US
(+)-3′-angeloyloxy-4′-keto-3′,4′-dihydroseselin for treating inflammation
US9408828B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9408828-B2 |
| Application number | US-201514742727-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 18, 2015 |
| Priority date | Jun 18, 2014 |
| Publication date | Aug 9, 2016 |
| Grant date | Aug 9, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides a compound, namely (+)-3′-Angeloyloxy-4′-keto-3′,4′-dihydroseselin (Pd-Ib) derived from Bupleurum malconense as the potential anti-inflammation drug. The present invention also relates to methods of preparing the compounds and using the same for treating inflammation.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating or alleviating inflammatory diseases or inflammation comprising administering an effective amount of a compound of structure (I), to a subject in need thereof. 2. The method of claim 1 , wherein said inflammatory diseases or inflammation comprises ulcerative colitis, Crohn's disease, and rheumatoid arthritis and said subject is human. 3. The method of claim 1 , wherein said effective amount of the compound being administered ranges from 2.43 to 9.72 mg/kg/day of the subject's body weight and said subject is human. 4. The method of claim 1 , wherein said effective amount of the compound being administered is 9.72 mg/kg/day of the subject's body weight and said subject is human. 5. The method of claim 3 , wherein said effective amount of the compound is administered daily via oral route and for at least seven consecutive days; said subject is human. 6. The method of claim 4 , wherein said effective amount of the compound is administered daily via oral route and for at least seven consecutive days; and said subject is human.
Assignees
Inventors
Classifications
Coumarins, e.g. psoralen · CPC title
- A61K31/366Primary
having six-membered rings, e.g. delta-lactones · CPC title
Mouth and digestive tract, i.e. intraoral and peroral administration · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9408828B2 cover?
- The present invention provides a compound, namely (+)-3′-Angeloyloxy-4′-keto-3′,4′-dihydroseselin (Pd-Ib) derived from Bupleurum malconense as the potential anti-inflammation drug. The present invention also relates to methods of preparing the compounds and using the same for treating inflammation.
- Who is the assignee on this patent?
- Univ Hong Kong Baptist Univ, Changshu Res Inst Of Hong Kong Baptist Univ
- What technology area does this patent fall under?
- Primary CPC classification A61K31/366. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Aug 09 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).